Rong Zhou Sells 3,187 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Key Points

• Executive insider sale: EVP Rong Zhou sold 3,187 Amphastar shares for approximately $75,309, reducing their ownership by 1.85% to 169,203 shares.
• Quarterly results beat expectations: Amphastar reported quarterly earnings of $0.91 per share versus the $0.62 consensus estimate, while revenue reached $183.9 million, above the $179.9 million forecast.
• Mixed analyst outlook: The stock carries an average “Reduce” rating, with six Hold ratings and two Sell ratings and an average price target of $22.50, below its reported trading price of $23.84.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) EVP Rong Zhou sold 3,187 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $23.63, for a total value of $75,308.81. Following the sale, the executive vice president owned 169,203 shares in the company, valued at $3,998,266.89. This trade represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock traded up $0.10 during trading hours on Thursday, hitting $23.84. 469,751 shares of the company were exchanged, compared to its average volume of 447,368. The firm has a fifty day simple moving average of $20.48 and a 200 day simple moving average of $20.59. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals, Inc. has a 52-week low of $16.65 and a 52-week high of $29.78. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 14.11, a P/E/G ratio of 4.57 and a beta of 0.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The business had revenue of $183.90 million for the quarter, compared to the consensus estimate of $179.92 million. Research analysts predict that Amphastar Pharmaceuticals, Inc. will post 2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wells Fargo & Company raised their target price on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Bank of America reissued an "underperform" rating and issued a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, July 21st. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Finally, Wall Street Zen raised shares of Amphastar Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 8th. Six investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Reduce" and an average target price of $22.50.

Institutional Trading of Amphastar Pharmaceuticals

Large investors have recently modified their holdings of the business. AQR Capital Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 82.0% during the first quarter. AQR Capital Management LLC now owns 53,638 shares of the company's stock worth $1,555,000 after purchasing an additional 24,167 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Amphastar Pharmaceuticals by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company's stock worth $652,000 after buying an additional 613 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Amphastar Pharmaceuticals by 43.0% in the 1st quarter. Intech Investment Management LLC now owns 60,289 shares of the company's stock worth $1,748,000 after buying an additional 18,133 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth $1,865,000. Finally, Invesco Ltd. raised its position in shares of Amphastar Pharmaceuticals by 7.7% during the 2nd quarter. Invesco Ltd. now owns 386,971 shares of the company's stock valued at $8,885,000 after buying an additional 27,828 shares in the last quarter. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source